Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society of Immunotherapy of Cancer

Rapport Therapeutics Appoints Chief Financial Officer

Flare Therapeutics Announces First Patients Dosed in First-in-Human Phase 1 Clinical Study of FX-909 in Advanced Solid Malignancies, Including Urothelial Cancer

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

CARGO Therapeutics Announces Appointment of Ginna Laport, MD, as Chief Medical Officer